Primary outcome
BI 1467335 resulted in dose-dependent inhibition of plasma AOC3 activity, with >80% reductions from baseline seen by Week 4 with doses of ≥3 mg. Relative to baseline values, mean AOC3 activity at Week 12 (24 hours post dose) was 26.5% in the BI 1467335 1 mg dose group, (indicating 73.5% inhibition), 10.4% in the 3 mg group (indicating 89.6% inhibition), 5.0% in the 6 mg group (95.0% inhibition) and 3.3% in the 10 mg group (96.7% inhibition); mean plasma AOC3 activity in placebo recipients was 90.4%, indicating that no substantial change was observed with placebo and thus meeting the primary endpoint (Supplementary Table 